The Catalyst

Most Recent Posts

10.20.13 | By Karl Uhlendorf

Earlier this month, Bill Chin announced on this blog that PhRMA will be hosting a forum along with the Alzheimer’s Association and the Alzheimer’s Drug Discovery Foundation on Wednesday, October 23rd.

10.18.13 | By Kaelan Hollon

Tuesday began Medicare Part D Open Enrollment. With the program still going strong 10 years after it was enacted, Part D represents a significant milestone for patients.

10.18.13 | By Stephanie Fischer

The cultural anthropologist Margaret Mead once said, “Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.”

10.17.13 | By Jay Taylor

As the 12 countries negotiating the Trans-Pacific Partnership (TPP) approach the finish line after years of hard work on an ambitious agreement, there remains quite a bit of work left to be done. Now that all the low hanging fruit has been picked, the most difficult issues remain to be finalized. Not surprisingly, intellectual property (IP) is one of those issues 

10.15.13

Across the nation, millions of seniors and disabled Americans have access to innovative medicines through the Medicare prescription drug program (Part D). This year, we’re celebrating the 10-year anniversary of the program’s enactment, as well as taking note of the important feedback provided by those individuals who rely on it.

10.11.13 | By Kaelan Hollon

Every day, our industry strives to connect patients, families and advocates from across the globe who share our common goals of preventing diseases, improving health and saving lives. Those strong voices of innovators and stakeholders working tirelessly to address pressing medical challenges, and many medical breakthroughs wouldn’t be possible today or in the future without them.

10.10.13 | By John Castellani

In the last 20 years, the Prescription Drug User Fee Act (PDUFA) has resulted in timelier patient access to more than 1,500 new drugs and biologics, decreasing review times for these treatments by more than 60 percent.

10.09.13 | By Kaelan Hollon

We’re excited to host a guest blog post by Steve Pasierb, the passionate CEO of The Partnership at Drugfree.org. We’ve been longtime partners with The Partnership, and Steve’s blog will be the first of regular updates about what’s new in The Partnership at Drugfree.org’s world.

10.08.13 | By Stephanie Fischer

The world’s biopharmaceutical research companies continually strive to develop new medicines that prevent diseases, improve patient health, and help save lives.  There are currently more than 5,000 medicines in development globally.

10.04.13 | By Kaelan Hollon

The significant disease progress we've made reminds us to not only recognize and appreciate what we've already accomplished on behalf of patients, but also to look into the future and determine what more can be done.

10.02.13 | By Dr. Bill Chin

The best and the brightest spanning the innovation ecosystem have been trying for years to unlock the mysteries of Alzheimer’s disease with the common goals of delaying, treating or outright preventing progression of the disease. Further, there are a number of public and private initiatives underway and no shortage of related conferences and meetings.

09.30.13 | By Matt Bennett

In 1992, under the Prescription Drug User Fee Act (PDUFA), the U.S. Food and Drug Administration (FDA) began collecting fees from biopharmaceutical companies to provide much needed resources to keep new medicines moving through the approval process and into the hands of patients. 

09.30.13 | By John Castellani

In 2003, through the Medicare Modernization Act, Congress established the Medicare prescription drug benefit - better known as Part D. Ten years later, at a cost significantly below initial estimates, the program is successfully providing affordable access to prescription drugs for more than 30 million seniors and people with disabilities.

09.27.13 | By Kaelan Hollon

From programs that provide access to medicines, to the development of innovative new treatments, the recent progress we’ve made is staggering.

09.27.13 | By Scott LaGanga

Millions of patients around the world depend on innovative medicines to help them live long, healthy lives. Every time I travel to a different country, I am reminded of this fact. Just last week in Tokyo, PhRMA EVP for Advocacy Chip Davis specifically addressed how the innovative new medicines our member companies develop have enhanced the country’s health care system.

Pages